

## Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa), Epclusa Pellets

Reference Number: DE.PHAR.268

Effective Date: 01.23

Last Review Date: 05.23

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Sofosbuvir/velpatasvir (Epclusa<sup>®</sup>) is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.

### FDA Approved Indication(s)

Epclusa is indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection:

- Without cirrhosis or with compensated cirrhosis
- With decompensated cirrhosis for use in combination with ribavirin (RBV)

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Epclusa is **medically necessary** when the following criteria are met:

### I. Initial Approval Criteria

#### A. Chronic Hepatitis C Infection (must meet all):

1. Diagnosis of chronic HCV infection as evidenced by detectable serum HCV RNA levels by quantitative assay in the last 6 months;
2. Confirmed HCV genotype is 1, 2, 3, 4, 5 or 6;  
*\*Chart note documentation and copies of lab results are required*
3. **For Epclusa Tablet Requests:** Member must use **authorized generic version of Epclusa**, unless contraindicated or clinically significant adverse effects are experienced;
4. Documentation of the treatment status of the member (treatment-naive or treatment-experienced);
5. Documentation of cirrhosis status of the member (no cirrhosis, compensated cirrhosis, or decompensated cirrhosis);
6. Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious disease specialist, or provider who has expertise in treating HCV based on a certified training program (*see Appendix F*);
7. Age  $\geq$  3 years;
8. Life expectancy  $\geq$  12 months with HCV treatment;
9. Member agrees to participate in a medication adherence program meeting both of the following components:

- a. Medication adherence monitored by pharmacy claims data or member report;
  - b. Member's risk for non-adherence identified by adherence program or member/prescribing physician follow-up at least every 4 weeks;
10. Prescribed regimen is consistent with an FDA or AASLD-IDSa recommended regimen (*see Section V Dosage and Administration for reference*);
11. Dose does not exceed one of the following (a, b, or c):
- a. Adult and pediatric members with body weight  $\geq 30$  kg: sofosbuvir/velpatasvir 400 mg/100 mg (1 tablet) per day;
  - b. Pediatric members 3 years of age and older with body weight  $< 17$  kg: sofosbuvir/velpatasvir 150 mg/37.5 mg per day;
  - c. Pediatric members 3 years of age and older with body weight 17 kg to  $< 30$  kg: sofosbuvir/velpatasvir 200 mg/50 mg per day.

**Approval duration: up to a total of 12 weeks\***

(\*Approved duration should be consistent with a regimen in Section V Dosage and Administration)

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Chronic Hepatitis C Infection (must meet all):**

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Documentation supports that member is currently receiving Eplusa for chronic HCV infection and has recently completed at least 60 days of treatment with Eplusa;
2. Member is responding positively to therapy;
3. Dose does not exceed one of the following (a, b, or c):
  - a. Adult and pediatric members with body weight  $\geq 30$  kg: sofosbuvir/velpatasvir 400 mg/100 mg (1 tablet) per day;
  - b. Pediatric members 3 years of age and older and body weight  $< 17$  kg: sofosbuvir/velpatasvir 150 mg/37.5 mg per day;
  - c. Pediatric members 3 years of age and older and body weight 17 kg to  $< 30$  kg: sofosbuvir/velpatasvir 200 mg/50 mg per day.

**Approval duration: up to a total of 12 weeks\***

(\*Approved duration should be consistent with a regimen in Section V Dosage and Administration)

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

AASLD: American Association for the Study of Liver Diseases

FDA: Food and Drug Administration

HBV: hepatitis B virus

HCC: hepatocellular carcinoma

HCV: hepatitis C virus

HIV: human immunodeficiency virus

IDSA: Infectious Diseases Society of America

NS3/4A, NS5A/B: nonstructural protein

PegIFN: pegylated interferon

RBV: ribavirin

RNA: ribonucleic acid

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): Epclusa and RBV combination regimen is contraindicated in patients for whom RBV is contraindicated. Refer to the RBV prescribing information for a list of contraindications for RBV.
- Boxed warning(s): risk of hepatitis B virus (HBV) reactivation in patients coinfecting with HCV and HBV.

*Appendix D: Direct-Acting Antivirals for Treatment of HCV Infection*

| Brand Name   | Drug Class     |   |   |                                |                 |
|--------------|----------------|---|---|--------------------------------|-----------------|
|              | NS5A Inhibitor | Nucleotide Analog NS5B Polymerase Inhibitor | Non-Nucleoside NS5B Palm Polymerase Inhibitor | NS3/4A Protease Inhibitor (PI) | CYP3A Inhibitor |
| Epclusa*     | Velpatasvir    | Sofosbuvir                                  |   |                                |                 |
| Harvoni*     | Ledipasvir     | Sofosbuvir                                  |   |                                |                 |
| Mavyret*     | Pibrentasvir   |   |   | Glecaprevir                    |                 |
| Sovaldi      |                | Sofosbuvir                                  |   |                                |                 |
| Viekira Pak* | Ombitasvir     |   | Dasabuvir                                     | Paritaprevir                   | Ritonavir       |
| Vosevi*      | Velpatasvir    | Sofosbuvir                                  |   | Voxilaprevir                   |                 |
| Zepatier*    | Elbasvir       |   |   | Grazoprevir                    |                 |

\*Combination drugs

*Appendix E: General Information*

- HBV reactivation is a Black Box Warning for all direct-acting antiviral drugs for the treatment of HCV. HBV reactivation has been reported when treating HCV for patients co-infected with HBV, leading to fulminant hepatitis, hepatic failure, and death, in some cases. Patients should be monitored for HBV reactivation and hepatitis flare during

HCV treatment and post-treatment follow-up, with treatment of HBV infection as clinically indicated.

- Child-Pugh Score:

|                | 1 Point                                  | 2 Points                                  | 3 Points   |
|----------------|--|---|--|
| Bilirubin      | Less than 2 mg/dL<br>Less than 34 umol/L | 2-3 mg/dL<br>34-50 umol/L                 | Over 3 mg/dL<br>Over 50 umol/L                       |
| Albumin        | Over 3.5 g/dL<br>Over 35 g/L             | 2.8-3.5 g/dL<br>28-35 g/L                 | Less than 2.8 g/dL<br>Less than 28 g/L               |
| INR            | Less than 1.7                            | 1.7 - 2.2                                 | Over 2.2   |
| Ascites        | None                                     | Mild / medically controlled               | Moderate-severe / poorly controlled                  |
| Encephalopathy | None                                     | Mild / medically controlled<br>Grade I-II | Moderate-severe / poorly controlled.<br>Grade III-IV |

*Child-Pugh class is determined by the total number of points: A = 5-6 points; B = 7-9 points; C = 10-15 points.*

#### Appendix F: Healthcare Provider HCV Training

Acceptable HCV training programs and/or online courses include, but are not limited to the following:

- Hepatitis C online course (<https://www.hepatitisc.uw.edu/>): University of Washington is funded by the Division of Viral Hepatitis to develop a comprehensive, online self-study course for medical providers on diagnosis, monitoring, and management of hepatitis C virus infection. Free CME and CNE credit available.
- Fundamentals of Liver Disease (<https://liverlearning.aasld.org/fundamentals-of-liver-disease>): The AASLD, in collaboration with ECHO, the American College of Physicians (ACP), CDC, and the Department of Veterans Affairs, has developed Fundamentals of Liver Disease, a free, online CME course to improve providers' knowledge and clinical skills in hepatology.
- Clinical Care Options: <http://www.clinicaloptions.com/hepatitis.aspx>
- CDC training resources: <https://www.cdc.gov/hepatitis/resources/professionals/trainingresources.htm>

#### V. Dosage and Administration

| Indication  | Dosing Regimen                                      | Maximum Dose  | Reference             |
|---|---|---|-----------------------|
| Genotype 1-6:<br>Without cirrhosis or with compensated cirrhosis, treatment-naïve or treatment-experienced* patient | One tablet PO QD for 12 weeks                       | Adult/Peds ≥ 30 kg: sofosbuvir 400 mg /velpatasvir 100 mg (one tablet) per day; | FDA-approved labeling |
| Genotype 1-6:<br>With decompensated cirrhosis, treatment-naïve or treatment-experienced* patient                    | One tablet PO QD with weight-based RBV for 12 weeks | Peds 17 to < 30 kg: sofosbuvir 200 mg   |                       |

| Indication   | Dosing Regimen  | Maximum Dose  | Reference                           |
|--|---|---|-------------------------------------|
|  | (RBV-ineligible patient may use: one tablet PO QD for 24 weeks) <sup>‡</sup>  | /velpatasvir 50 mg per day;                                     |                                     |
| Genotype 1-6:<br>Treatment-naïve and treatment-experienced patients, post-liver transplant with compensated cirrhosis or without cirrhosis | One tablet PO QD for 12 weeks   | Peds < 17 kg:<br>sofosbuvir 150 mg /velpatasvir 37.5 mg per day |                                     |
| Genotype 1-6:<br>With decompensated cirrhosis in whom prior sofosbuvir- or NS5A inhibitor-based treatment failed                           | One tablet PO QD with weight-based RBV for 24 weeks <sup>‡</sup>  | One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day       | AASLD-IDSA (updated September 2021) |
| Genotype 1-6:<br>Treatment-naïve and treatment-experienced patients, post-liver transplant with decompensated cirrhosis                    | One tablet PO QD with RBV (starting at 600 mg and increased as tolerated) for 12 weeks (treatment naïve) or 24 weeks (treatment experienced) <sup>‡</sup> | One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day       | AASLD-IDSA (updated September 2021) |
| Genotype 3 with NS5A Y93H polymorphism:<br>Treatment-naïve with compensated cirrhosis or treatment-experienced* without cirrhosis patient  | One tablet PO QD with weight-based RBV for 12 weeks <sup>‡</sup>  | One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day       | AASLD-IDSA (updated September 2021) |

AASLD/IDSA treatment guidelines for chronic hepatitis C infection are updated at irregular intervals; refer to the most updated AASLD/IDSA guideline for most accurate treatment regimen.

\*From clinical trials, treatment-experienced refers to previous treatment with NS3/4A protease inhibitor (telaprevir, boceprevir, or simeprevir) and/or peginterferon/RBV unless otherwise stated

‡ Off-label, AASLD-IDSA guideline-supported dosing regimen

## VI. Product Availability

- Tablets: sofosbuvir 400 mg with velpatasvir 100 mg, sofosbuvir 200 mg with velpatasvir 50 mg
- Oral pellets: sofosbuvir 200 mg with velpatasvir 50 mg, sofosbuvir 150 mg with velpatasvir 37.5 mg

## VII. References

1. Epclusa Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; April 2022. Available at [http://www.gilead.com/~media/files/pdfs/medicines/liver-disease/epclusa/epclusa\\_pi.pdf](http://www.gilead.com/~media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf). Accessed May 1, 2022.

2. American Association for the Study of Liver Diseases/ Infectious Disease Society of America (AASLD-IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. Last updated September 29, 2021. Available at: <https://www.hcvguidelines.org/>. Accessed May 1, 2022.
3. CDC. Hepatitis C Q&As for health professionals. Last updated August 7, 2020. Available at: <https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm>. Accessed May 2, 2022.

| Reviews, Revisions, and Approvals                             | Date  | P&T Approval Date |
|---|-------|-------------------|
| Policy created  | 11.21 | 11.21             |
| Change duration of therapy to 12weeks per 365 from first fill | 5.23  | 6.23              |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.